Adalta

Adalta Financial Leverage

The Financial Leverage (Equity Multiplier) of Adalta (1AD.AX) as of Nov 5, 2026 is 4.65. In the previous year, Financial Leverage (Equity Multiplier) was -3.58 — a change of -229.92% (higher).

Financial Leverage

4.65

YoY

-229.92%

Last updated:

Financial Leverage (Equity Multiplier) of Adalta is 2026 4.65 . Financial Leverage (Equity Multiplier) of Adalta was 2025 -3.58 . It decreases by -229.92% higher compared to the previous year.

The Adalta Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2019
1.24 AUD
Jan 1, 2020
1.87 AUD
Jan 1, 2021
1.42 AUD
Jan 1, 2022
1.98 AUD
Jan 1, 2023
4.05 AUD
Jan 1, 2024
2.74 AUD
Jan 1, 2025
-3.58 AUD
Jan 1, 2026
4.65 AUD
The Adalta Financial Leverage history
YEARFinancial LeverageYoY
4.65-229.92%
-3.58-230.42%
2.74-32.21%
4.05+104.50%
1.98+39.72%
1.42-24.06%
1.87+50.13%
1.24+14.02%
1.09+4.35%
1.04+3.34%
1.01-26.22%
1.37-48.50%
2.66—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adalta Stock analysis

What does Adalta do? AdAlta Ltd. operates as a biotechnology company that discovers, develops, and commercializes protein based therapeutics. The firm is engaged in the development of therapeutic products from its i-body platform. The firm has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patient’s immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patient’s immune system to recognize and kill diseased cells such as cancer. The company develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. The company evaluates several CXCR4 i-bodies. Adalta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Adalta stock

Financial Leverage (Equity Multiplier) of Adalta is 4.65 in 2026.

Financial Leverage (Equity Multiplier) of Adalta changed from -3.58 to 4.65, representing a -229.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Adalta since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Adalta with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Adalta

All Key Metrics — Adalta